Literature DB >> 21389772

EMT: a new vision of hypoxia promoting cancer progression.

Jian Jiang1, Ya-ling Tang, Xin-hua Liang.   

Abstract

A hypoxic microenvironment plays a critical role in the development and progression of tumors. The epithelial to mesenchymal transition (EMT) is a process by which epithelial cells lose their polarity and are converted to a mesenchymal phenotype, which is regarded as a critical event in morphogenetic changes during embryonic development, wound healing, and cancer metastasis. Recent advances in our understanding of the molecular pathways that govern the association of hypoxia with malignant tumors point to the epithelial to mesenchymal transition (EMT). The hypoxic microenvironment common to cancer cells emerges as an important factor in the induction of a pathological EMT, which is a key link in cancer progression. This review presents the potential molecular mechanisms underlying the hypoxia/HIF-dependent regulation of the EMT in cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389772     DOI: 10.4161/cbt.11.8.15274

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  115 in total

Review 1.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

Review 2.  The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms.

Authors:  Yue Teng; Xu Li
Journal:  Clin Exp Metastasis       Date:  2013-10-26       Impact factor: 5.150

3.  Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus.

Authors:  Ji Hee Ha; Jeremy D Ward; Rangasudhagar Radhakrishnan; Muralidharan Jayaraman; Yong Sang Song; Danny N Dhanasekaran
Journal:  Oncotarget       Date:  2016-06-21

4.  Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma.

Authors:  Ser Yue Loo; Jayshree L Hirpara; Vijay Pandey; Tuan Zea Tan; Celestial T Yap; Peter E Lobie; Jean Paul Thiery; Boon Cher Goh; Shazib Pervaiz; Marie-Véronique Clément; Alan Prem Kumar
Journal:  Antioxid Redox Signal       Date:  2016-08-20       Impact factor: 8.401

5.  HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT.

Authors:  Yang Liu; Yawei Liu; Xiaolu Yan; Yuan Xu; Fei Luo; Jing Ye; Han Yan; Xiaojun Yang; Xiaodan Huang; Jianping Zhang; Guozhong Ji
Journal:  Tumour Biol       Date:  2014-05-20

Review 6.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

Review 7.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

8.  Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

Authors:  Chun-Xiong Zhao; Chun-Li Luo; Xiao-Hou Wu
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

Review 9.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

Review 10.  In Vitro Innovation of Tendon Tissue Engineering Strategies.

Authors:  Maria Rita Citeroni; Maria Camilla Ciardulli; Valentina Russo; Giovanna Della Porta; Annunziata Mauro; Mohammad El Khatib; Miriam Di Mattia; Devis Galesso; Carlo Barbera; Nicholas R Forsyth; Nicola Maffulli; Barbara Barboni
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.